We recently published a list of Jim Cramer’s Recent Thoughts on These 15 Stocks. In this article, we are going to take a look at where ImmunityBio (NASDAQ:IBRX) stands against other stocks that Jim Cramer discussed recently.
On Monday, Mad Money host Jim Cramer addressed the market’s reaction to the recent U.S. debt downgrade by Moody’s.
“Stories like the US debt downgrade story from Friday, they are classic… Stories that scare people out of very fine stocks that could otherwise make them rich. And sure enough, when Moody’s downgraded the debt of the United States on Friday, the last of the three big rating agencies to do so, the market opened hideously as the get out now crowd took action. They fled. Then the market rebounded.”
READ ALSO: Jim Cramer Put These 12 Stocks Under the Spotlight and 15 Stocks on Jim Cramer’s Radar.
Cramer warned that such panic is not a one-off. He mentioned that there will be many other ‘get out now’ calls issued ahead. He said that the warnings often come from sources who either do not fully grasp the situation or are motivated by less transparent reasons. In his view, some are simply uninformed, while others may be experienced short sellers using fear as a tactic to move markets in their favor.
Even if the issues these fear-driven stories point to do materialize, Cramer believes they are manageable. He called out the overuse of the term “stagflation,” often wielded by bearish commentators to provoke anxiety. He acknowledged how difficult it can be to resist the persuasive nature of such arguments. Still, he encouraged investors to stay the course as he added, “You’ll have to stick with me and we’ll sit through this.”
“Let me give you the bottom line: The crucial thing that we in the media can do, and I say this as someone who talks to more individual veterans than almost anyone in the universe, and certainly more than anyone in the media, is simply cool it with the fear mongering and cut off guests who advocate it. A little history and some constructive thought would go a lot further if your goal is not to inflame, but to inform.”
Our Methodology
For this article, we compiled a list of 15 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on May 19. We listed the stocks in ascending order of their hedge fund sentiment as of the fourth quarter of 2024, which was taken from Insider Monkey’s database of over 1,000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.
ImmunityBio, Inc. (NASDAQ:IBRX)
Number of Hedge Fund Holders: 15
Upon receiving a caller’s inquiry about ImmunityBio, Inc. (NASDAQ:IBRX), Cramer stated:
“IBRX is not a great stock, immunity bio. I’ve looked at it for a very, very long time. I don’t like the fact that they are, they’ve been losing money forever. I am not in their camp.”
ImmunityBio. (NASDAQ:IBRX) develops advanced immunotherapies targeting cancer and infectious diseases, focusing on cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. Its lead candidate, Anktiva, is FDA-approved for use with bacillus calmette-guérin in treating certain bladder cancers.
On May 20, Piper Sandler raised its rating on ImmunityBio (NASDAQ:IBRX) to Overweight from Neutral and increased the price target to $5 from $4.25. The firm highlighted the company’s work on Anktiva, t-haNK, and M-ceNK cell therapies, and DNA vaccines aimed at reactivating the immune system to fight cancer. Anktiva has shown a strong start in treating non-muscle invasive bladder cancer, with projected sales of $83.5 million in 2025. Piper believes there is potential for broader use of Anktiva, despite the FDA’s refusal to file a letter for one of its bladder cancer indications.
Overall, IBRX ranks 12th on our list of stocks that Jim Cramer discussed recently. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center